Beijing Beilu Pharmaceutical Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Beijing Beilu Pharmaceutical Company Limited with three other
companies in this sector in China:
Wuhan Hiteck Biological Pharma Co Ltd
sales of 590.87 million Chinese Renmimbi [US$85.83 million]
of which 93%
was Medicine Manufacture),
Zhejiang Shapuaisi Pharmaceutical Co Ltd
(607.34 million Chinese Renmimbi [US$88.22 million]
of which 54%
was Eye drops), and
Hainan Poly Pharm Co Ltd
(623.90 million Chinese Renmimbi [US$90.63 million]
of which 39%
was Antiallergic drugs).
Beijing Beilu Pharmaceutical Company Limited reported sales of 608.05 million Chinese Renmimbi (US$88.33 million)
December of 2018.
increase of 16.4%
versus 2017, when the company's sales were 522.54 million Chinese Renmimbi.
Sales at Beijing Beilu Pharmaceutical Company Limited have increased during each of the previous five years
(and since 2013, sales have increased a total of 83%).
Sales of Pharmaceutical Sales saw an increase
16.5% in 2018, from
519.81 million Chinese Renmimbi to 605.55 million Chinese Renmimbi.
Not all segments of Beijing Beilu Pharmaceutical Company Limited experienced an increase in sales in 2018:
sales of Other Operation fell 8.1% to 2.50 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).